中药提取物声敏剂在声动力治疗动脉粥样硬化中的应用

doi:10.3969/j.issn.1007-2861.2016.03.012

摘要/Abstract

摘要：

目前, 动脉粥样硬化引起的心血管疾病发生率越来越高, 除昂贵的介入和搭桥治疗术外, 寻求一种简单、有效且经济的治疗方法至关重要. 声动力治疗是一种无创、安全的治疗方式, 其在动脉粥样硬化治疗中的应用很有前景. 声动力治疗中使用的药物为声敏剂, 是影响其疗效的主要因素之一. 研究人员一直致力于探讨不同种类声敏剂所带来的声动力效果在动脉粥样硬化治疗中起到的不同作用. 近年来, 在声敏剂的筛选研究中发现, 中药提取物有很大的潜在声敏剂价值. 简要总结了目前对声动力治疗机制及大黄素、姜黄素及其衍生物和金丝桃素作为声敏剂在声动力治疗动脉粥样硬化中的相关进展.

关键词: 动脉粥样硬化, 声敏剂 , 中药提取物 , 声动力治疗

Abstract:

At present, morbidity of cardiovascular disease induced by atherosclerosis (AS) is becoming higher. Besides expensive intervention and bypass surgery, it is extremely urgent to look for a popular and effective method for the treatment of AS. Sonodynamic therapy (SDT) is a non-invasive targeting therapy, and is promising for AS treatment based on the SDT-related research. Sonosensitizer, an application of SDT, is an entry points of the SDT investigation. Therefore, different sonodynamic effects with different sonosensitizers are investigated by researchers in AS treatment. In recent years, it is found that sonosensitizers derived from Chinese herb products play an important role in SDT, exerting potent sonodynamic effects for AS treatment. This review briefly summarizes the action of SDT and relevant development of SDT with emodin, curcumin, hypericin and its derived derivatives as sonosensitizers for AS treatment.

Key words: atherosclerosis, Chinese herb product , sonosensitizer , sonodynamic therapy

寇佳媛1, 姜月晴1, 田野1,2, 杨力明1. 中药提取物声敏剂在声动力治疗动脉粥样硬化中的应用[J]. 上海大学学报(自然科学版), 2016, 22(3): 318-325.

KOU Jiayuan1, JIANG Yueqing1, TIAN Ye1,2, YANG Liming1. Application of sonosensitizers derived from Chinese herb products in sonodynamic therapy for atherosclerosis treatment[J]. Journal of Shanghai University（Natural Science Edition）, 2016, 22(3): 318-325.

参考文献

[1] Lotta L A. Genome-wide association studies in atherothrombosis [J]. European Journal of Internal Medicine, 2010, 21(2): 74-78.
[2] Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association [J]. Circulation, 2014, 131(4): e29-e322.
[3] Ferguson J J, Kereiakes D J, Adgey A A, et al. Safe use of platelet GP Ⅱb/Ⅲa inhibitors [J]. American Heart Journal, 1998, 135(4): D40-D51.
[4] Neuvonen P J, Mikko N, Backman J T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance [J]. Clinical Pharmacology and Therapeutics, 2007, 80(6): 565-581.
[5] Rockson S G, Lorenz D P, Cheong W F, et al. Photoangioplasty an emerging clinical cardiovascular role for photodynamic therapy [J]. Circulation, 2000, 102(5): 591-596.

[6] Chen H, Zhou X, Yu G, et al. Recent progress in development of new sonosensitizers for sonodynamic cancer therapy [J]. Drug Discovery Today, 2014, 19(4): 502-509.
[7] Sgolastra F, Petrucci A, Gatto R, et al. Photodynamic therapy in the treatment of chronic periodontitis: a systematic review and Meta-analysis [J]. Lasers in Medical Science, 2013, 28(2): 669-682.
[8] Maria K, Konstantinos T, Archontoula M, et al. Vulnerable plaque and inflammation: potential clinical strategies [J]. Curr Pharm Des, 2011, 17(37): 4190-4209.
[9] Martijn T, Paul B, Schellens J H M, et al. Photodynamic therapy in oncology [J]. Oncologist, 2006, 11(9): 1034-1044.
[10] Yumita N, Nishigaki R, Umemura K, et al. Hematoporphyrin as a sensitizer of cell-damaging effect of ultrasound [J]. Jpn J Cancer Res, 1989, 80(3): 219-222.
[11] Bailey M R, Khokhlova V A, Sapozhnikov O A, et al. Physical mechanisms of the therapeutic effect of ultrasound (a review) [J]. Acoustical Physics, 2003, 49(4): 369-388.
[12] Kuroki M, Hachimine K H, Shibaguchi H, et al. Sonodynamic therapy of cancer using novel sonosensitizers [J]. Anticancer Research, 2007, 27(6A): 3673-3678.
[13] Shi J, Chen Z, Wang B, et al. Reactive oxygen species-manipulated drug release from a smart envelope-type mesoporous titanium nanovehicle for tumor sonodynamic-chemotherapy [J]. ACS Applied Materials and Interfaces, 2015, 7(51): 28554-28565.
[14] Rosenthal I, Sostaric J Z, Riesz P. Sonodynamic therapy—a review of the synergistic effects of drugs and ultrasound [J]. Ultrasonics Sonochemistry, 2004, 11(6): 349-363.
[15] Hirotomo S, Hirofumi T, Motomu K, et al. Sonodynamic cancer therapy: a non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer [J]. Anticancer
Research, 2011, 31(7): 2425-2429.
[16] Baker K G, Robertson V J, Duck F A. A review of therapeutic ultrasound: biophysical effects [J]. Physical Therapy, 2001, 81(7): 1351-1358.
[17] Suslick K S. Ultrasound: its chemical, physical and biological effects [M]. Weinheim: Vch Publishers, 1988.
[18] Apfel R E. Acoustic cavitation: a possible consequence of biomedical uses of ultrasound [J]. British Journal of Cancer Supplement, 1982, 5(1): 140-146.
[19] David C, Conor M E, Colin F, et al. Treating cancer with sonodynamic therapy: a review [J]. International Journal of Hyperthermia the Official Journal of European Society for Hyperthermic Oncology North American Hyperthermia Group, 2015, 31(2): 107-117.
[20] Li Y, Pan W, Ping Z, et al. Apoptosis induced by sonodynamic treatment by protoporphyrin Ⅸ on MDA-MB-231 cells [J]. Ultrasonics, 2012, 52(4): 490-496.
[21] Xin S, Xu H, Jing S, et al. Real-time detection of intracellular reactive oxygen species and mitochondrial membrane potential in THP-1 macrophages during ultrasonic irradiation for optimal sonodynamic therapy [J]. Ultrasonics Sonochemistry, 2015, 22: 7-14.
[22] Zheng L, Sun X, Zhu X, et al. Apoptosis of THP-1 derived macrophages induced by sonodynamic therapy using a new sonosensitizer hydroxyl acetylated curcumin [J]. PLoS One, 2014, 9(3): e93133.
[23] Cheng J, Sun X, Guo S, et al. Effects of 5-aminolevulinic acid-mediated sonodynamic therapy on macrophages [J]. International Journal of Nanomedicine, 2013, 8(1): 669-676.

[24] Tao L, Hui J, Sun Q R, et al. Neuroprotective effects of emodin in rat cortical neurons against beta-amyloid-induced neurotoxicity [J]. Brain Research, 2010, 1347(1): 149-160.
[25] Qin H, Mazhar N, Yuen F W, et al. In vitro anti-fibrotic activities of herbal compounds and herbs [J]. Nephrology Dialysis Transplantation, 2009, 24(10): 3033-3041.
[26] Cai J, Razzak A, Hering J, et al. Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro [J]. Journal of Parenteral and Enteral
Nutrition, 2008, 32(2): 357-360.
[27] Esther B, Geert C, Nico H, et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy [J]. FASEB Journal, 2006, 20(6): 756-758.
[28] Gao Q, Wang F, Guo S, et al. Sonodynamic effect of an anti-inflammatory agent—emodin on macrophages [J]. Ultrasound in Medicine and Biology, 2011, 37(9): 1478-1485.
[29] Buhrmann C, Mobasheri A, Busch F, et al. Curcumin modulates NF-B-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase-Akt pathway [J]. Journal of Biological Chemistry, 2011, 286(32): 28556-28566.
[30] Samuhasaneeto S, Thong-Ngam D, Kulaputana O, et al. Curcumin decreased oxidative stress, inhibited NF-kappaB activation, and improved liver pathology in ethanol-induced liver injury in rats [J]. Journal of Biomedicine and Biotechnology, 2009, 2009(1): 981963.
[31] Issei D, Yunkyung H, Noriyuki Y, et al. Inhibitory effect of curcumin on IMP dehydrogenase, the target for anticancer and antiviral chemotherapy agents [J]. Bioscience Biotechnology and Biochemistry, 2010, 74(1): 185-187.
[32] Wang F, Gao Q, Guo S, et al. The sonodynamic effect of curcumin on THP-1 cell-derived macrophages [J]. Biomed Research International, 2013, 2013(1): 121-128.
[33] Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence [J]. European Neuropsychopharmacology, 2011, 21(12): 841-860.
[34] Ehrenshaft M, Roberts J E, Mason R P. Hypericin-mediated photooxidative damage of-crystallin in human lens epithelial cells [J]. Free Radical Biology and Medicine, 2013, 60:
347-354.
[35] Boˇzin B, Kladar N, Gruji´c N, et al. Impact of origin and biological source on chemical composition, anticholinesterase and antioxidant properties of some St. John’sWort Species (Hypericum spp., Hypericaceae) from the central balkans [J]. Molecules, 2013, 18(18): 11733-11750.
[36] Li X, Gao L, Zheng L, et al. The efficacy and mechanism of apoptosis induction by hypericin-mediated sonodynamic therapy in THP-1 macrophages [J]. International Journal of
Nanomedicine, 2015, 10: 821-838.
[37] Kerb R, Brockm¨oller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin [J]. Antimicrobial Agents and Chemotherapy, 1996, 40(9): 2087-2093.
[38] Lv Y, Fang M, Zheng J, et al. Low-intensity ultrasound combined with 5-aminolevulinic acid administration in the treatment of human tongue squamous carcinoma [J]. Cellular Physiology and Biochemistry, 2012, 30(2): 321-333.[39] He Y, Xia X, Xu C, et al. 5-aminolaevulinic acid enhances ultrasound-induced mitochondrial damage in K562 cells [J]. Ultrasonics, 2010, 50(8): 777-781.
[40] Barbara K, Kristjan P. ALA and its clinical impact, from bench to bedside [J]. Photochemical and Photobiological Sciences, 2008, 7(3): 283-289.
[41] Song W, Cui H, Zhang R, et al. Apoptosis of SAS cells induced by sonodynamic therapy using 5-aminolevulinic acid sonosensitizer [J]. Anticancer Research, 2011, 31(1): 39-45.
[42] Chen H, Gao W, Yang Y, et al. Inhibition of VDAC1 prevents Ca2+-mediated oxidative stress and apoptosis induced by 5-aminolevulinic acid mediated sonodynamic therapy in THP-1 macrophages [J]. Apoptosis, 2014, 19(12): 1712-1726.
[43] Rensen S S M, Doevendans P A F M, Eys G J J M V. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity [J]. Netherlands Heart Journal, 2007, 15(3):
100-108.
[44] Chen K H, Guo X, Ma D, et al. Dysregulation of HSG triggers vascular proliferative disorders [J]. Nature Cell Biology, 2004, 6(9): 872-883.
[45] Dan J, Sun X, Li W, et al. 5-aminolevulinic acid-mediated sonodynamic therapy promotes phenotypic switching from dedifferentiated to differentiated phenotype via reactive oxygen species and p38 mitogen-activated protein kinase in vascular smooth muscle cells [J]. Ultrasound in Medicine and Biology, 2015, 41(6): 1681-1689.
[46] Moore K J, Tabas I. Macrophages in the pathogenesis of atherosclerosis [J]. Cell, 2011, 145(3): 341-355.
[47] Ira T, Kevin J W, Jan B. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications [J]. Circulation, 2007, 116(16): 1832-1844.
[48] Wang H, Yang Y, Chen H, et al. The predominant pathway of apoptosis in THP-1 macrophagederived foam cells induced by 5-aminolevulinic acid-mediated sonodynamic therapy is the mitochondria-caspase pathway despite the participation of endoplasmic reticulum stress [J]. Cellular Physiology and Biochemistry, 2014, 33(6): 1789-1801.
[49] Li Z, Sun X, Guo S, et al. Rapid stabilisation of atherosclerotic plaque with 5-aminolevulinic acid-mediated sonodynamic therapy [J]. Thrombosis and Haemostasis, 2015, 114(4): 793-803.
[50] Tian F, Yao J, Yan M, et al. 5-aminolevulinic acid-mediated sonodynamic therapy inhibits RIPK1/RIPK3-dependent necroptosis in THP-1-derived foam cells [J]. Scientific Reports, 2016, 6: 21992.
[51] Chung J, Chen C, Paw B H. Heme metabolism and erythropoiesis [J]. Current Opinion in Hematology, 2012, 19(3): 156-162.
[52] Peng C, Li Y, Liang H, et al. Detection and photodynamic therapy of inflamed atherosclerotic plaques in the carotid artery of rabbits [J]. Journal of Photochemistry and Photobiology B Biology, 2011, 102(1): 26-31.
[53] Moore K J, Sheedy F J, Fisher E A. Macrophages in atherosclerosis: a dynamic balance [J]. Nature Reviews Immunology, 2013, 13(10): 709-721.
[54] Guo S, Sun X, Cheng J, et al. Apoptosis of THP-1 macrophages induced by protoporphyrin Ⅸ-mediated sonodynamic therapy [J]. International Journal of Nanomedicine, 2013, 8(13): 2239-2246.